Stablecoin Development Corporation · AMEX:SDEV
Stablecoin Development — NovaBay Pharmaceuticals — Investor Presentation (December 2016)
39 slides from Stablecoin Development's investor presentation, December 2016
Slide 1: Going Beyond Antibiotics
Going Beyond Antibiotics® Developing and Commercializing Anti‐Infective Products that Fight Infections without Giving Rise to Resistance December, 2016 NYSE MKT: NBY www.novabay.com
Slide 2: Forward-Looking Statements
Forward‐Looking Statements This presentation contains forward‐looking statements, within the meaning of applicable U.S. securities laws, which statements can, in some cases, be identified with terms such as “project,” “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,”
Slide 3: Mark Sieczkarek - Background
Mark Sieczkarek‐Background 35 years in the Life Sciences‐ Large and Small Companies Pharmaceutical, Consumer, Diagnostics and Medical Devices Finance Sales & Marketing Manufacturing Mergers and Acquisitions General Management Bristol‐Myers‐Senior Vice‐President Sanofi‐COO of US Dia
Slide 4: Neutrophils – Our first line of defense against infections
Neutrophils – Our first line of defense against infections Produce broad spectrum antimicrobials that do not give rise to resistance Pathogen Neutrophil Red Blood Cells 4
Slide 5: The Foundation of NovaBay Technology
The Foundation of NovaBay Technology Develop Anti‐Microbial Molecules that Mimic Those Produced by Neutrophils White Blood Cell Natural molecule: Natural Molecule: Hypochlorous Acid (HOCl) N‐Chlorotaurine (NCT) Fast Acting, broad spectrum anti‐microbial, difficult to mfg Longer Acting, Effective; BU
Slide 6: Two Distinct Anti-Infective Product Groups
Two Distinct Anti-Infective Product Groups Neutrox® Aganocides® Based Products Lead: Auriclosene® (FDA Cleared – Commercial) (Advanced Clinical) Urology UCBE (Urinary Catheter Blockage and Encrustation) WW: $700M WW: $600M 300,000 Chronically catheterized in U.S. 100,000 Chronic blockage • Paraplegi
Slide 7: Going Beyond Antibiotics
Going Beyond Antibiotics® Harnessing the Anti‐Infective Power of White Blood Cell Chemistry Developing and Commercializing Anti‐Infective Products that Fight Infections without Giving Rise to Resistance NYSE MKT: NBY www.novabay.com September 19, 2016
Slide 8: NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market September 19, 2016 NYSE MKT: NBY www.novabay.com
Slide 9: Strategic Focus on Eye Care
Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa
Slide 10: Anti-biofilm, Anti-Toxin, Does not generate resistance
Does not ✓ generate Resistance ✓ Bacterial Removal ✓ Mechanical Debridement ✓ Anti‐biofilm Activity ✓ Anti‐Toxin 10
Slide 11: 41 Million Potential Patients in U.S.
41 Million Potential Patients in U.S. Blepharitis 24M Dry Eye 6M Contact lens Surgery ‐ Catarac intolerance 3M 4M Retinal injections Surgery ‐ Lasik 3M 1M 11
Slide 12: What is Blepharitis?
What is Blepharitis? Blepharon, Greek “eyelid” + itis – inflammatory disease Signs and symptoms ‒ Itchy, sore, red eyelids; eyelids stick together; burning, gritty sensation High incidence ‒ 37% of patients seen by ophthalmologists ‒ 47% of patients seen by optometrists Most common cause is st
Slide 13: Case Study – Compelling Results
Case Study – Compelling Results with 13
Slide 14: Only two Ingredients = Pure Hypochlorous Acid + Saline
Only two Ingredients = 1. Pure Hypochlorous Acid + 2. Saline Oasis OCuSoft SteriLid Lid and Lash LIDCLENZ VisiCleanse Eye Scrub Water , PEG‐80 Sorbitan Water , PEG 80 , Sorbitan Water, Poloxamer, non‐foaming Water, Water USP Laurate , Sodium Laurate , Sodium Polyethylene, pH balanced Cocamidopropyl
Slide 15: Growing Commercial Presence
Growing Commercial Presence 15
Slide 16: Avenova lid and lash hygiene
Daily |& Lash Hygiene “Neu trox hal Pure Hypochorous
Slide 17: Addressing Major U.S. Markets
Addressing Major U.S. Markets 17
Slide 18: Market Coverage
Market Coverage 43 Direct Medical Reps In Key Metro Areas Northeast (11): Albany, Brooklyn, Manhattan, Nassau County, White Plains, Cherry Hill, Boston, Hartford, Patterson, Wash, DC, Philadelphia Midwestern (10): Chicago‐No, Chicago‐So, Detroit, St. Louis, Buffalo, St. Paul, Kansas City, KS, Clevel
Slide 19: Covering Major Markets
Covering Major Markets N™®vaBay PHARMA
Slide 20: Net Sales ($000)
Net Sales ($000) 3,088 2,578 1,003 33% Direct Buy & Bill Sales Prescriptions Sales 914 1,580 1,366 1,118 1,115 70% 2,085 67% 806 813 1,664 797 465 684 425 465 30% 553 321 40 122 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 20
Slide 21: History of Net Operating Losses
History of Net Operating Losses (in thousands) 500 Net Operating Loss ($000) ‐ Breakeven Adj Q3 for one‐time exps: (500) ‐ Move related ‐ Warrant repricing (1,000) (1,500) (1,697) (2,000) (2,013) (2,500) (2,843) (2,206) (2,982) (3,000) (3,487) (3,500) (3,786) (4,150) (4,078) (4,113) (4,000) (4,500)
Slide 22: Avenova Phased Commercial Strategy
Avenova Phased Commercial Strategy 22
Slide 23: Avenova Phased Commercial Strategy
Avenova Phased Commercial Strategy Phase 1 – Initial Launch ‒ 2015 launch targeted two sales channels at introductory pricing 1. Sales Reps detailing directly to MD’s and OD’s ‐ Primary emphasis ‐ Most efficient approach to seed the market 2. Prescription sales ‐ Once doctors comfortable with prod
Slide 24: Key Opinion Leader Endorsements
Key Opinion Leader Endorsements 24
Slide 25: KOL from Across U.S. Support
KOL from Across U.S. Support Ophthalmic Advisory Board Dr. Eric Donnenfeld Past president of Ocular Microbiology and Immunology Group and serves on the Board of Directors of American Society of Cataract and Refractive Surgery. Dr. Donnenfeld has published over 175 journal articles, and >20 book chap
Slide 26: KOLs from Across U.S. Support
KOLs from Across U.S. Support Optometry Advisory Board Dr. Arthur Epstein Director of Dry Eye – Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; heads practice’s Dry‐Eye – Ocular Surface Disease Center and serves as Director of Clinical Research. Internationally r
Slide 27: Advertising and Collateral Marketing Materials
Advertising Placements in Top Trade Journals Collateral Marketing Materials 27 27
Slide 28: Interactive Website
Interactive Website Find a Physician Find a Pharmacy 28
Slide 29: Media Coverage Growing
Media Coverage Growing 29
Slide 30: Media Coverage Growing
Media Coverage Growing Article: “Avenova With Neutrox Is ‘Breakthrough’ in Fight Against Contact Lens Intolerance” 30
Slide 31: Media Coverage Growing
Media Coverage Growing Article: “New Therapy Introduced for Chronic Dry Eye” 31
Slide 32: Media Coverage Growing
Media Coverage Growing Article: “Dry Eye: A Growing Problem in an Aging Population” 32
Slide 33: Media Coverage Growing
Media Coverage Growing Article: “New Treatments for Contact Lens Intolerance On The Rise” 33
Slide 34: Media Coverage Growing
Media Coverage Growing Article: “Did You Know Your Eye Makeup Could Be Making You Sick?” 34
Slide 35: Media Coverage Growing
Media Coverage Growing Article: “Spotlight on Demodex: Eliminating the Mite‐y Menace” 35
Slide 36: Media Coverage Growing
Media Coverage Growing RECEIVE THE OPTOMETRIC|OFFICE 9 [smtec SEARCH HOME ARCHIVES VIEWPOINTS DEPARTMENTS INSTRUMENTATION CONTACT LENSES THERAPEUTICS PATIENT CARE Issue Date: Optometric Office Mar 2016 p &@S Baa AN RX FOR HEALTHY LASHES AND LIDS Avenova provides long-term comfort for patients with c
Slide 37: Financial Overview
Financial Overview Million Market Cap (12/2/16) $60 Cash (9/30/16) $9.4 Debt $0 Shares Outstanding (Preliminary 9/30/16) 15 Shareholders Equity (9/30/16) $6.8
Slide 38: Strategic Focus on Eye Care
Strategic Focus on Eye Care 2 Initiatives Targeting Commercial Growth and Cash Flow Breakeven 1. Continue revenue Growth from sales of Avenova® ‒ Large, poorly served U.S. market with 41 million potential patients ‒ Commercial strategy producing significant quarterly sales growth ‒ Leveraging substa
Slide 39: NovaBay Pharmaceuticals
NovaBay Pharmaceuticals Commercializing Avenova® Lid and Lash Hygiene in the U.S. Eye Care Market NYSE MKT: NBY www.novabay.com December, 2016
NovaBay Pharmaceuticals — Investor Presentation (December 2016) on 6ix